Benzinga · Sep 16, 2026
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating
William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.
ZN
NASDAQ · ZNTL
Zentalis Pharmaceuticals, Inc.
Healthcare · Biotechnology
$3.08
Down-$0.02 (-0.65%)
Updated Sep 18, 2026, 11:42 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 104.4M
- P/E ratio
- -0.64
- Dividend yield
- 0.00%
- 52-week range
- $1.21 – $6.95
- Volume
- 1.09M
- Avg. volume
- 673.52K
Price performance
ZNTL price history
1M range · 0 trading sessions · Daily adjusted prices
ZNTL does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ZNTL news
The latest Smart Investors Daily articles mentioning ZNTL.
Stock researchCompany · Overview
ZNTL research
Overview
Company profile and research snapshot.
Company profile
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | William Blair | Outperform | — |
| Jul 23, 2026 | Rodman & Renshaw | Buy | — |
| Jul 17, 2026 | Mizuho | Outperform | — |
| Apr 10, 2026 | Guggenheim | Buy | — |
| Mar 27, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zentalis Pharmaceuticals, Inc. (ZNTL) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 2:35 PM EDTCompany ParticipantsJulie...
Yahoo · Sep 2, 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference, Boston, MA. Fireside discussion, September 8, 2026, 4:30p
Yahoo · Sep 1, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 269,000 shares of the Company’s common stock to four (4
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
